Trump Approves the Firing of FDA Chief Califf

Summary

President Trump has approved the dismissal of FDA Commissioner Marty Makary following disputes over flavored e-cigarette approvals, controversial drug rejections like Replimune’s, and internal agency management Pharmexec+ 3. Kyle Diamantas will serve as acting commissioner while the administration seeks a leader more aligned with its deregulatory agenda ahead of the midterms Yahoo Finance+ 2.

Impact Analysis

So, Trump is basically clearing the deck at the FDA, and it’s a massive signal for anyone in the tobacco or biotech space. Makary was trying to play the ‘scientific rigor’ card—demanding large placebo trials and blocking flavored vapes—which clearly didn’t sit well with the White House’s deregulatory push Pharmexec+ 3. By ousting him now, Trump is signaling a pivot toward a much more industry-friendly, ‘fast-track’ FDA ahead of the midterms Yahoo Finance.

The immediate trade is obviously tobacco; we’ve already seen Turning Point and BAT move on the expectation that flavored e-cigarettes finally get the green light Investing.com. But the real alpha might be in ‘beaten-down biotech.’ Look at Replimune—their stock tanked when Makary’s FDA rejected them, but it’s already bouncing on news of his exit Reuters+ 2. This suggests a lower bar for clinical data moving forward. Bottom line: we’re moving from a ‘public health’ FDA to a ‘pro-business’ FDA. Watch for a successor who prioritizes speed over scrutiny. I’d be long tobacco and looking for tactical entries in small-cap biotech names with pending CRLs.